Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep Franchise
November 24, 2025
Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep FranchiseNovember 24, 2025 Eversheds Sutherland is pleased to have advised Azurity Pharmaceuticals on its acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies. The strategic transaction further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States. With the acquisition, Azurity welcomes more than 50 colleagues from Sebela’s commercial and support teams. Read Azurity’s press release here. The Eversheds Sutherland team was led by Partner Mike Voynich (Corporate), with support from Partner Pete Pappas (Intellectual Property), Special Counsel Anna Halsey (Intellectual Property), Senior Associate Adam Byrne (Corporate) and Associate Haley Klass (Corporate). Key contacts
Latest InsightsLatest News
Latest Eventslegal updates September 23, 2026 Commercially Connected shorts - 23 September 2026 legal updates September 16, 2026 Commercially Connected shorts - 16 September 2026 legal updates September 15, 2026 CMA places public procurement at the centre of its growth agenda legal updates September 14, 2026 Global Sustainability & ESG Insights - August 2026 client news September 21, 2026 All change: Eversheds Sutherland advises DfT on Chiltern Railways transitio... firm news August 26, 2026 Eversheds Sutherland strengthens top-ranked pensions practice with appointm... client news August 13, 2026 Eversheds Sutherland advises H.I.G. Capital on investment in Phoenix ME client news August 13, 2026 Eversheds Sutherland reappointed to the UK's Government Commercial Agency l... |